-
The first Claudin 18.2/PD-L1 double antibody was approved for clinical use
Time of Update: 2021-04-28
Q-1802 is a bispecific antibody that is independently developed by Qiyu Biologics using its antibody engineering technology platform and has independent intellectual property rights that can simultaneously target PD-L1 and Claudin 18.
2/PD-L1 bispecific antibody that passed the US FDA IND.
-
AstraZeneca's CLL drug Calquence is approved by NICE in the UK
Time of Update: 2021-04-28
CompilationFan DongdongA few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
-
Market | Children's Drug Market Analysis and Policy Inventory: China Chapter
Time of Update: 2021-04-28
In 2021 The 2020 medical insurance catalogue (2800 types of Western medicines and proprietary Chinese medicines) that will be formally implemented on March 1 adds several child medicines; although the protection of children’s medicines is gradually increasing, it accounts for the proportion of the overall variety There is still a significant gap.
-
Roche withdraws PD-L1 inhibitor Tecentriq for bladder cancer indications in the U.S.
Time of Update: 2021-04-28
As of July 2018, the data detection committee of the IMvigor130 study found that newly-treated locally advanced or metastatic urothelial cancer patients who were not suitable for cisplatin chemotherapy received Tecentriq single-agent first-line treatment, and patients with low PD-L1 expression survived As a result, the FDA has restricted Tecentriq's first-line treatment of bladder cancer as a restriction on the positive expression of PD-L1.
-
Hengrui Medicine's carmustine for injection was approved by the U.S. FDA
Time of Update: 2021-04-28
Carmustine for injection was first developed by EMCURE PHARMACEUTICALS LTD and was approved in the United States in 1977 under the trade name BICNU.
After inquiries, there are currently 4 foreign companies that have approved generic carmustine for injection on the market.
-
The first in China! Idea Di AXL Inhibitor Application for Clinical
Time of Update: 2021-04-28
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
-
A rout ten years ago drove domestic HPLC out of mainstream pharmaceutical companies
Time of Update: 2021-04-28
If you want to choose the most important detection equipment in a pharmaceutical company, it may be high-performance liquid chromatography (HPLC).
However, a rout ten years ago brought everything to an abrupt end, and domestic HPLC was driven out of mainstream pharmaceutical companies.
-
Enhua Pharmaceutical's Class 1 chemical drug NH102 hydrochloride tablets was approved for clinical use
Time of Update: 2021-04-28
On March 15th, Enhua Pharmaceuticals issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" for 3 specifications of NH102 Hydrochloride Tablets, a category 1 chemical drug approved and issued by NMPA, and will start clinical trials in the near future .
-
CStone's platinib enters China for approval and is expected to usher in the first approved RET inhibitor
Time of Update: 2021-04-28
Public information shows that the indication for this application of the drug is a locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patient who has previously received platinum-containing chemotherapy and has a positive RET gene fusion.
-
Five new drugs are planned to be breakthrough therapies from Junshi, Microchip, Novo Nordisk...
Time of Update: 2021-04-28
include:Junshi Biologics' PD-1 Teriprizumab is used in the first-line treatment of mucosal melanoma;Novo Nordisk's long-acting GLP-1 inhibitor Semaglutide (Semaglutide) is used in the treatment of NASH;The first class of Microchip's new drug Cioroni is used in the treatment of ovarian cancer;Yuheng Bio/WuXi Biologics PD-1 monoclonal antibody Sepalizumab (GLS-010) is used in the treatment of cervical cancer;Shanghai Ruixing's oxynidone capsule is used for chronic hepatitis B fibrosis.
-
FDA extends the review period for supplementary new drug applications for AbbVie RINVOQ due to safety considerations
Time of Update: 2021-04-28
CompileLiLiOn March 17, according to foreign media reports, AbbVie announced that the US FDA has extended the review period for the anti-inflammatory drug RINVOQ Supplemental New Drug Application (sNDA) for the treatment of active psoriatic arthritis (PsA) in adults.
-
The pharmacy selling this health product was sent to trial for prosecution or sentenced for it
Time of Update: 2021-04-28
According to reports, in June 2020, the Xiejiaji Branch of the Huainan Public Security Bureau filed and investigated the suspected sale of toxic and harmful health food in a pharmacy in Xiejiaji based on the clues transferred by the district market supervision bureau.
-
CDE intends to identify Hengrui CDK4/6 inhibitors and Junshi anti-PD-1 for breakthrough therapy
Time of Update: 2021-04-28
In August 2019, Junshi announced the results of an open-label phase IB clinical trial of teriprizumab combined with the anti-angiogenic drug axitinib for the treatment of advanced mucosal melanoma.
-
Lingkang Pharmaceutical's Ceftizoxime Sodium for Injection Received "Drug Registration Approval"
Time of Update: 2021-04-28
On June 14, 2012, Meida Pharm submitted its first domestic drug registration application to the State Food and Drug Administration for ceftizoxime sodium for injection and was accepted.
-
2021 AACR | Chinese companies such as BeiGene, Corning Jerry, and Tianjing Bio will make their debut
Time of Update: 2021-04-28
At this conference, Corning Jerry will announce the data of an open, multi-center Phase 1b/2 clinical study (study number: KN046-203) of KN046 combined with paclitaxel in the treatment of patients with advanced triple-negative breast cancer in the form of a poster.
-
Indian Prime Minister Modi vaccinated the first dose of the new crown vaccine, which was developed locally in India
Time of Update: 2021-04-28
Modi said that through the efforts of Indian doctors and scientists, India was able to quickly develop a vaccine and strongly supported the global fight against the new crown pneumonia epidemic.
-
Novo Nordisk launches clinical trials of long-acting insulin in China once a week
Time of Update: 2021-04-28
The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.
-
Eli Lilly appoints Jiang Yifei as Vice President of New Diabetes Products Division
Time of Update: 2021-04-28
On March 17, Eli Lilly officially announced that Chen Jun, the current Vice President of Eli Lilly’s China Diabetes Products Division, will leave Eli Lilly for personal reasons to seek external career development opportunities.
-
Market | Rising stars are rising, the CDK4/6 inhibitor market is getting bigger and bigger
Time of Update: 2021-04-28
However, the latest overall survival (OS) of the Phase III MONALEESA-7 study of Kisqali combined with endocrine therapy for breast cancer is close to 5 years (58.
However, Ibrance combined with endocrine therapy in the treatment of HR+/HER2-early breast cancer in two phase III clinical studies, PALLAS and PENELOPE-B, suffered Waterloo.
-
Pfizer's PF-06882961 clinical trial application was approved for the treatment of type 2 diabetes
Time of Update: 2021-04-28
Danuglipron (code name: PF-06882961 tablets) is an oral small molecule GLP-1 receptor agonist developed by Pfizer.
The company will also initiate a phase IIb clinical trial to test the efficacy of this oral small molecule GLP-1 receptor agonist in the treatment of patients with NASH.
